<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02882711</url>
  </required_header>
  <id_info>
    <org_study_id>HSC-MS-16-0020</org_study_id>
    <nct_id>NCT02882711</nct_id>
  </id_info>
  <brief_title>The UTHealth Ketamine Project</brief_title>
  <official_title>A Naturalistic Study of Serial Infusion of Low-dose Ketamine for Treatment Resistant Depressive Disorders in an Academic Psychiatric Hospital: The UTHealth Ketamine Project</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Health Science Center, Houston</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The University of Texas Health Science Center, Houston</source>
  <brief_summary>
    <textblock>
      The primary objective of this study is to determine the effectiveness of serial infusions of&#xD;
      intravenous (IV) ketamine in adults with treatment resistant depression (TRD).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Thus, in the current study we want to naturalistically explore the antidepressant effects of&#xD;
      serial slow IV infusions (40 minutes) of ketamine at a dose of 0.5 mg/kg, over a treatment&#xD;
      period of 8 weeks in an academic psychiatric hospital. This is a minimal sedation treatment.&#xD;
      The primary outcome measure of this study will be remission estimated based on the severity&#xD;
      of depressive scores. After the 8 weeks of treatment, there will be a four week observational&#xD;
      period. During the observational period, participants will receive treatment as usual and&#xD;
      will be contacted over the phone for follow-up questions regarding their overall health&#xD;
      status, mood and clinical state. They will also complete a neurocognitive task at the end of&#xD;
      the 4 week observational period&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Increasing off-label practice of IV ketamine administration for treatment-resistant depression.&#xD;
  </why_stopped>
  <start_date type="Actual">November 7, 2016</start_date>
  <completion_date type="Actual">August 16, 2017</completion_date>
  <primary_completion_date type="Actual">August 16, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety Will be Measured Through Number of Adverse Events</measure>
    <time_frame>Baseline through week 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy of Treatment Will be Measured on of Clinical Global Impressions (CGI)</measure>
    <time_frame>Baseline, week 8, week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of Depressive Symptoms as Assessed by the PHQ-9</measure>
    <time_frame>Baseline, week 8, week 12</time_frame>
    <description>The Patient Health Questionnaire (PHQ)-9 is the 9-item depression module from the full Patient Health Questionnaire (PHQ) PHQ-9 total score ranges from 0 to 27 (each of the 9 items can be scored from 0 (not at all) to 3 (nearly every day)), and a higher score indicates greater depression.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Treatment Resistant Depression</condition>
  <condition>Major Depressive Disorder</condition>
  <condition>Bipolar Disorder</condition>
  <arm_group>
    <arm_group_label>ketamine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketamine</intervention_name>
    <description>Ketamine will be infused (slow IV infusions of ketamine (0.5 mg/kg) over 40 minutes) twice weekly over a period of 4 weeks and weekly for the following 4 weeks of the study treatment period (8 weeks total).</description>
    <arm_group_label>ketamine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patients with major depressive disorder (MDD) or bipolar disorder (BD)&#xD;
&#xD;
          -  patients with documented treatment resistant disorder (TRD) (according to Diagnostic&#xD;
             Statistical Manual (DSM-IV TR)), and who have failed (defined as patient does not&#xD;
             reach remission within the 8 week trial of an antidepressant or combination at a&#xD;
             therapeutic dose) of at least two trials of first line evidence-based treatments&#xD;
             and/or electroconvulsive therapy (ECT)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Being younger than 18 of age or older than 65.&#xD;
&#xD;
          -  Diagnosed with intellectual disability, e.g. mental retardation (MR),&#xD;
             neurodegenerative diseases, e.g. early-onset neurocognitive disturbances such as&#xD;
             frontotemporal dementia (FTD) or behavioral disorders, e.g. adult onset Attention&#xD;
             Deficit Hyperactivity Disorder (ADHD).&#xD;
&#xD;
          -  Diagnosed with bipolar disorder not otherwise specified (BD-NOS) or rapid cycling BD&#xD;
&#xD;
          -  Diagnosed with personality disorders (PD).&#xD;
&#xD;
          -  Previously or currently diagnosed with psychosis (schizoaffective disorder - SAD) or&#xD;
             schizophrenia - SCZ).&#xD;
&#xD;
          -  Current major medical problems that affect brain anatomy, neurochemistry, or function,&#xD;
             e.g., obstructive sleep apnea requiring Continuous Positive Airway Pressure (CPAP),&#xD;
             liver insufficiency, kidney insufficiency, cardiovascular problems, systemic&#xD;
             infections, cancer, auto-immune diseases, and any brain disorder (seizure disorder,&#xD;
             stroke, dementia, degenerative neurologic diseases); history of any brain diseases,&#xD;
             including seizures, stroke, meningitis, encephalitis, dementia, degenerative brain&#xD;
             diseases, and head injury with loss of consciousness for any period of time.&#xD;
&#xD;
          -  Diagnosed specifically with a cardiovascular disorders such as Arrhythmias, Chronic&#xD;
             Heart Failure, Myocardial Infarction (MI) or suffering from Chronic Obstructive&#xD;
             Pulmonary Disease (COPD) or asthma. Suffering from uncontrolled hypertension or&#xD;
             diastolic BP over 100. Cardiac clearance prior to enrolling in the study/medical&#xD;
             records from physician will be required per patient's primary care physician (PCP).&#xD;
&#xD;
          -  Patients with increased risk of laryngospasm, active upper respiratory infections,&#xD;
             respiratory depression, increased intracranial pressure, hyperthyroidism, or&#xD;
             porphyria.&#xD;
&#xD;
          -  Current substance abuse or dependence. Only patients who achieved stable, full&#xD;
             remission for at least 6 months will be included.&#xD;
&#xD;
          -  Pregnancy or Breast feeding. All female in reproductive age will undergo pregnancy&#xD;
             tests. Female participants will be required to provide evidence of use of&#xD;
             contraceptives during the course of the study.&#xD;
&#xD;
          -  Unable to understand the design and requirements of the study&#xD;
&#xD;
          -  Unable to sign the informed consent for any reason&#xD;
&#xD;
          -  An assigned responsible adult has provided assent to assist in patient's study&#xD;
             participation. The responsible adult agrees to be present at each study appointment as&#xD;
             well as provide transportation to study appointments for the patient.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Salih Selek, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Texas Health Science Center, Houston</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The University of Texas Health Science Center at Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>August 22, 2016</study_first_submitted>
  <study_first_submitted_qc>August 24, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 30, 2016</study_first_posted>
  <results_first_submitted>October 16, 2020</results_first_submitted>
  <results_first_submitted_qc>October 16, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">November 9, 2020</results_first_posted>
  <disposition_first_submitted>November 26, 2019</disposition_first_submitted>
  <disposition_first_submitted_qc>December 5, 2019</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">December 9, 2019</disposition_first_posted>
  <last_update_submitted>November 6, 2020</last_update_submitted>
  <last_update_submitted_qc>November 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The University of Texas Health Science Center, Houston</investigator_affiliation>
    <investigator_full_name>Salih Selek</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
    <mesh_term>Bipolar Disorder</mesh_term>
    <mesh_term>Depressive Disorder, Treatment-Resistant</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketamine</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 12, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/11/NCT02882711/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Four participants who were enrolled met exclusion criteria and therefore did not start the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Ketamine</title>
          <description>Ketamine: Ketamine will be infused (slow IV infusions of ketamine (0.5 mg/kg) over 40 minutes) twice weekly over a period of 4 weeks and weekly for the following 4 weeks of the study treatment period (8 weeks total).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ketamine</title>
          <description>Ketamine: Ketamine will be infused (slow IV infusions of ketamine (0.5 mg/kg) over 40 minutes) twice weekly over a period of 4 weeks and weekly for the following 4 weeks of the study treatment period (8 weeks total).</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Safety Will be Measured Through Number of Adverse Events</title>
        <time_frame>Baseline through week 12</time_frame>
        <population>This data was only collected for the 2 participants who completed the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Ketamine</title>
            <description>Ketamine: Ketamine will be infused (slow IV infusions of ketamine (0.5 mg/kg) over 40 minutes) twice weekly over a period of 4 weeks and weekly for the following 4 weeks of the study treatment period (8 weeks total).</description>
          </group>
        </group_list>
        <measure>
          <title>Safety Will be Measured Through Number of Adverse Events</title>
          <population>This data was only collected for the 2 participants who completed the study.</population>
          <units>adverse events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Efficacy of Treatment Will be Measured on of Clinical Global Impressions (CGI)</title>
        <time_frame>Baseline, week 8, week 12</time_frame>
        <population>Clinical Global Impressions (CGI) scale data was not collected for any participant</population>
        <group_list>
          <group group_id="O1">
            <title>Ketamine</title>
            <description>Ketamine: Ketamine will be infused (slow IV infusions of ketamine (0.5 mg/kg) over 40 minutes) twice weekly over a period of 4 weeks and weekly for the following 4 weeks of the study treatment period (8 weeks total).</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy of Treatment Will be Measured on of Clinical Global Impressions (CGI)</title>
          <population>Clinical Global Impressions (CGI) scale data was not collected for any participant</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Severity of Depressive Symptoms as Assessed by the PHQ-9</title>
        <description>The Patient Health Questionnaire (PHQ)-9 is the 9-item depression module from the full Patient Health Questionnaire (PHQ) PHQ-9 total score ranges from 0 to 27 (each of the 9 items can be scored from 0 (not at all) to 3 (nearly every day)), and a higher score indicates greater depression.</description>
        <time_frame>Baseline, week 8, week 12</time_frame>
        <population>PHQ-9 data was collected at baseline for all 6 participants who started the study. PHQ-9 data was not collected at week 8 or week 12 for 4 participants, per study protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Ketamine</title>
            <description>Ketamine: Ketamine will be infused (slow IV infusions of ketamine (0.5 mg/kg) over 40 minutes) twice weekly over a period of 4 weeks and weekly for the following 4 weeks of the study treatment period (8 weeks total).</description>
          </group>
        </group_list>
        <measure>
          <title>Severity of Depressive Symptoms as Assessed by the PHQ-9</title>
          <description>The Patient Health Questionnaire (PHQ)-9 is the 9-item depression module from the full Patient Health Questionnaire (PHQ) PHQ-9 total score ranges from 0 to 27 (each of the 9 items can be scored from 0 (not at all) to 3 (nearly every day)), and a higher score indicates greater depression.</description>
          <population>PHQ-9 data was collected at baseline for all 6 participants who started the study. PHQ-9 data was not collected at week 8 or week 12 for 4 participants, per study protocol.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.67" spread="9.501"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5" spread="5.657"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5" spread="5.657"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Ketamine</title>
          <description>Ketamine: Ketamine will be infused (slow IV infusions of ketamine (0.5 mg/kg) over 40 minutes) twice weekly over a period of 4 weeks and weekly for the following 4 weeks of the study treatment period (8 weeks total).</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>dissociation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Not reaching the target number of participants needed to achieve target power</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Salih Selek, M.D.</name_or_title>
      <organization>The University of Texas Health Science Center at Houston</organization>
      <phone>713-741-3936</phone>
      <email>salih.selek@uth.tmc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

